Clinical Trial Update: FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a stop-and-go strategy with FOLFOX plus panitumumab as first-line treatment for metastatic colorectal cancer without RAS mutation, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFOX
• Panitumumab (panitumumab)

Snippet

Sponsor: Federation Francophone de Cancerologie Digestive | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED